We then analyzed Nrf2 and EpCAM transcript levels by qRT-PCR and found that both transcripts were increased in cisplatin-resistant tumor cells (Fig. 3g), suggesting that resistance to cisplatin is due in part to an increased level of Nrf2 transcriptional activity and EpCAM overexpression. Here, NFE2L2 is linked to neoplasm.